Chronic Obstructive Pulmonary Disease (COPD)
Three-dimensional "super clusters" in patients with COPD could play a role in the progression of COPD to emphysema.
The FDA has approved Yupelri inhalation solution for the maintenance treatment of patients with COPD.
There may an increased risk for tuberculosis in patients with COPD within 3 years of inhaled corticosteroid use.
The overall rate of asthma-COPD overlap was 3.8%, with a maximum prevalence of 7.8% in Matlab, Bangladesh.
Half of patients with COPD report use of inhaler medications that are not in alignment with the current treatment recommendations.
Air-driven bronchodilator nebulization is preferable to oxygen-driven nebulization in patients experiencing acute COPD exacerbations.
The increased occurrence of periprocedural complications in patients with COPD was largely attributed to cardiac arrest, myocardial infarctions, and no-reflows.
Albuminuria was associated with greater lung function decline in patients with chronic obstructive pulmonary disease.
Cystic fibrosis transmembrane conductance regulator dysfunction is associated with worsened airway disease in patients with COPD.
No difference in mortality, but there may be an elevated risk for suicide with long-term benzodiazepine use in patients with COPD and comorbid PTSD.
Middle-aged testosterone replacement therapy users with COPD had a greater reduction in hospitalizations compared with nonusers.
Early pulmonary rehabilitation after hospitalization for an acute exacerbation of COPD was an effective intervention for reducing mortality.
The FDA has approved updated labeling for Stiolto Respimat to include COPD exacerbation data and a revised indication.
Patients who received a discharge care bundle after being hospitalized for an acute exacerbation of COPD had a lower rate of readmission.
Patients with chronic obstructive pulmonary disease who used opioids were more likely to be intubated during their hospitalization compared with nonopioid users
There was a trend toward a reduction in mortality in patients with COPD who received beta-blocker treatment compared with patients who did not.
Major cardiovascular adverse events were more common in the previous event subgroup, with 5.5% occurring in the aclidinium group and 6.2% in the placebo group.
Patients with severe COPD improved significantly in both endurance time and walking distance with the use of automatically titrated oxygen flow vs constant oxygen flow.
Treatment with prophylactic antibiotics was associated with a reduction in the frequency of COPD exacerbations and improved quality of life.
No meaningful associations were detected in procedural listing preferences and survival outcomes in patients with COPD or interstitial lung disease awaiting lung transplant.
Clinicians are eager for new therapies to address the damage to airways and lung parenchyma because no current therapy can completely reverse COPD damage.
After 12 months, patients in the Urban Training™ group had increased their number of daily steps by 816 compared with 64 steps in the usual care group.
Additional bronchodilation and hyperinflation reduction occurred in COPD when RPL554, an inhaled PDE 3 and 4 inhibitor, was combined with standard bronchodilators.
Changing pollination patterns, extreme weather events, rising sea levels, air pollution, and extreme temperatures all negatively affect respiratory conditions.
There were no statistically significant differences in mortality rates, rates of COPD exacerbations, lung inflammation, or serious adverse events between a once-daily combined inhaled corticosteroid/LABA and LAMA.
A total of 35% of heroin smokers screened positive for COPD.
Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and 0.55 for revefenacin 175mcg/day, 88mcg/day, and placebo, respectively.
No difference in exacerbations with indacaterol/glycopyrronium for non-frequently exacerbating COPD.
First bronchoscopic lung volume reduction using endobronchial valve performed at Temple University in Philadelphia, PA.
In their Complete Response Letter, the FDA stated that they require more clinical data to support approval.